Skip to Content

Generic Qinlock Availability

Last updated on July 7, 2021.

Qinlock is a brand name of ripretinib, approved by the FDA in the following formulation(s):

QINLOCK (ripretinib - tablet;oral)

  • Manufacturer: DECIPHERA PHARMS
    Approval date: May 15, 2020
    Strength(s): 50MG [RLD]

Has a generic version of Qinlock been approved?

No. There is currently no therapeutically equivalent version of Qinlock available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Qinlock. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,966,966

    Patent expiration dates:

    • August 12, 2040
      ✓ 
      Patent use: TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS HAVING PROGRESSED FROM A FIRST LINE ADMINISTRATION OF IMATINIB, A SECOND LINE ADMINISTRATION OF SUNITINIB, AND A THIRD LINE ADMINISTRATION OF REGORAFENIB
  • Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
    Patent 8,188,113
    Issued: May 29, 2012
    Inventor(s): Flynn; Daniel L. & Petillo; Peter A. & Kaufman; Michael D. & Patt; William C.
    Assignee(s): Deciphera Pharmaceuticals, Inc.

    The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

    Patent expiration dates:

    • July 27, 2030
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
    Patent 8,461,179
    Issued: June 11, 2013
    Assignee(s): Deciphera Pharmaceuticals, LLC

    The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound.

    Patent expiration dates:

    • June 7, 2032
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
    Patent 8,940,756
    Issued: January 27, 2015
    Assignee(s): Deciphera Pharmaceuticals, LLC

    The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound.

    Patent expiration dates:

    • June 7, 2032
      ✓ 
      Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • May 15, 2025 - NEW CHEMICAL ENTITY
    • May 15, 2027 -

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.